Q4 2024 Results Conference Call March 19, 2025 8:30 AM ETCompany ParticipantsDan Ferry - IR, LifeSci AdvisorsOfer Gonen - ...

Reported positive results from the Expanded Access Protocol (NEXT), reinforcing NexoBrid's clinical and real-world benefits across 29 burn centers in the U.S. The study included 239 patients (215 ...

If there are large wound care companies that you don’t see in this ... The first one on the left is NexoBrid. NexoBrid is a drug for eschar removal for severe burns. In order to remove SCAR in burns, ...

MediWound (NASDAQ:MDWD – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a report issued on Friday. Other research analysts have also issued reports about the company.

These results reinforce NexoBrid’s clinical benefits as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients, validating its significance as a ...

It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals ...

YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release ...

MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need ...